Cargando…
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort
Real-world evidence, directly comparing the effectiveness of interleukin (IL)17-inhibitors, IL23-inhibitors, tumour necrosis factor alpha (TNF-α)-inhibitors and an IL12/23-inhibitor in psoriasis, is scarce. The aim of this study was to directly compare the first-year effectiveness of biologic therap...
Autores principales: | VAN MUIJEN, Marloes. E., THOMAS, Sarah E., GROENEWOUD, Hans M. M., OTERO, Marisol E., OSSENKOPPELE, Paul M., NJOO, Marcellus D., DODEMONT, Sharon R. P., KOP, Else N., BERENDS, Maartje A. M., KOETSIER, Marjolein I. A., MOMMERS, Johannes M., KÖRVER, John E. M., TUPKER, Ron A., DE BRUIN-WELLER, Marjolein S., WEPPNER-PARREN, Lizelotte J. M. T., PETERS, Bas, KLEINPENNING, Marloes M., KUIJPERS, Astrid L. A., ARNOLD, W. Peter, VAN LÜMIG, Paula P. M., VAN DEN REEK, Juul M. P. A., DE JONG, Elke M. G. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Publication of Acta Dermato-Venereologica
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574692/ https://www.ncbi.nlm.nih.gov/pubmed/35356990 http://dx.doi.org/10.2340/actadv.v102.206 |
Ejemplares similares
-
Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study
por: ter Haar, E. L. M., et al.
Publicado: (2022) -
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study
por: ATALAY, Selma, et al.
Publicado: (2020) -
The Skin May Clear But the Arthritis Won’t Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy
por: van Muijen, Marloes E, et al.
Publicado: (2020) -
Unmet Personal Patient Needs in Psoriasis Patients with Low Disease Activity on Adalimumab, Etanercept or Ustekinumab
por: van Muijen, Marloes E., et al.
Publicado: (2021) -
Real-world Data Reveal Long Drug Survival for Guselkumab in Patients with Plaque Psoriasis
por: VAN MUIJEN, Marloes E., et al.
Publicado: (2022)